Evaxion Biotech A/S (NASDAQ:EVAX) versus Compass Therapeutics (NASDAQ:CMPX) Head to Head Contrast

Evaxion Biotech A/S (NASDAQ:EVAX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Profitability

This table compares Evaxion Biotech A/S and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	-451.63%	-149.27%
Compass Therapeutics	N/A	-26.07%	-24.49%

Insider & Institutional Ownership

11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Evaxion Biotech A/S has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Evaxion Biotech A/S and Compass Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
Compass Therapeutics	0	0	2	0	3.00

Evaxion Biotech A/S currently has a consensus target price of $11.00, indicating a potential upside of 172.28%. Compass Therapeutics has a consensus target price of $9.00, indicating a potential upside of 473.25%. Given Compass Therapeutics’ higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Evaxion Biotech A/S.

Earnings & Valuation

This table compares Evaxion Biotech A/S and Compass Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$70,000.00	301.27	-$22.12 million	($6.76)	-0.60
Compass Therapeutics	N/A	N/A	-$42.49 million	($0.34)	-4.62

Evaxion Biotech A/S has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Compass Therapeutics beats Evaxion Biotech A/S on 6 of the 10 factors compared between the two stocks.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.